Celldex Therapeutics is a biopharmaceutical company that focuses on developing antibody-based therapeutics to treat inflammatory diseases and cancers. Its drug candidates include CDX-0159, CDX-1140, and CDX-527, which are monoclonal and bispecific antibodies that target different receptors to inhibit activity or activate immune response. The company has collaboration and license agreements with various organizations to develop its innovative therapies and is headquartered in Hampton, New Jersey.